GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (NAS:NEUP) » Definitions » Common Stock

NEUP (Neuphoria Therapeutics) Common Stock : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics Common Stock?

Neuphoria Therapeutics's annual common stock declined from Jun. 2022 ($149.76 Mil) to Jun. 2023 ($0.00 Mil) but then stayed the same from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($0.00 Mil).


Neuphoria Therapeutics Common Stock Historical Data

The historical data trend for Neuphoria Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuphoria Therapeutics Common Stock Chart

Neuphoria Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 101.80 142.90 149.76 - -

Neuphoria Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 159.30 - - -

Neuphoria Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Neuphoria Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
100 Summit Dr, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.